

March 23, 2015

World Journal of Gastroenterology

Room 903, Building D, Ocean International Center

No. 62 Dongsihuan Zhonglu, Chaoyang District

Beijing 100025, China

Dear editor,

Please find the enclosed edited manuscript in Word format (file name ESPS Ms No 16727 - Review.doc).

**Title:** Perioperative Chemotherapy for Resectable Gastric Cancer: MAGIC and Beyond

**Authors:** Audrey H Choi, MD, Joseph Kim, MD, Joseph Chao, MD

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 16727

The manuscript has been revised according to the suggestions of reviewers:

1. Format has been updated.
2. Revision has been made according to the suggestions of the reviewers.
  - a. **Reviewer 02941534:** The authors have summarized neoadjuvant treatment options for gastric cancer. Trastuzumab was approved for the treatment of HER2(+) metastatic or advanced gastric cancer. The role of trastuzumab and dual anti-

HER2 blockade in the perioperative section should be discussed according to the ongoing phase I/II trials.

*i. The results of the Trastuzumab for Gastric Cancer (ToGA) study have been added to the editorial, as well as a preview of several phase I/II and II/III trials involving trastuzumab in combination with chemotherapy agents and monoclonal antibodies for the treatment of HER2-positive resectable gastric cancer.*

**b. Reviewer 02977393:** The authors have reviewed chemotherapy and radiation in relation to surgery for gastric cancer. They analyse the existing high-level clinical trials supporting the use of various neoadjuvant and adjuvant therapies for resectable gastric cancer. Their editorial is meaningful to clinical practice. The study is done carefully. This paper is acceptable for publication.

**c. Reviewer 03017454:** Authors summarized the situation of perioperative therapy for resectable gastric cancer. Manuscript was well organized. The following are major comments. 1. As author mentioned, the regional difference of clinical background between Asian and western countries is very important to correctly interpret the results of clinical trials in gastric cancer. Maybe, it would be helpful to describe more detailed this background. 2. Author referred many key trials. However, the details of each trial were described only for a few trials. It would be better to describe more. 3. In gastric cancer, ERBB2 is a validated biomarker for anti-ERBB2 therapy. The current situation of ERBB2 targeting therapy in perioperative therapy should be described.

*i. A brief description regarding the differences in biology, diagnosis and treatment patterns between Asian and Western populations has been added. Each trial was described in further detail and summarized in a table. As described previously, current and upcoming trials on anti-HER2 therapy have been added.*

*d. Reviewer 01220166:* I read the paper with interests, entitled “Perioperative Chemotherapy for Resectable Gastric Cancer: MAGIC and Beyond” by Choi AH et al. My comments are as follow. The authors reviewed the strategy of perioperative chemotherapy for resectable gastric cancer including results of the recent phase III trials. It is interesting and educational paper consists of important information. This review article is generally well written; however, additional figures or tables showing the various contents described in the text would be helpful to convince the readers. For instance, could you summarize the main results of the trials as Tables or Figures with core tips?

*i. The reviewer’s point is well-taken. The protocols and results of the major and upcoming trials in gastric cancer were added in a summarizing table.*

3. References and typesetting were corrected

Thank you again for considering our manuscript for publication in the World Journal of Gastroenterology.

Sincerely,

Joseph Chao, MD

Department of Medical Oncology

1500 E. Duarte Rd., Duarte, Ca 91010

Phone: (626) 218-9200; Fax: (626) 301-8233

Email: [jchao@coh.org](mailto:jchao@coh.org)